Skip to contentE
Endovia Health Sciences, Inc.
E
EDVAEndovia Health Sciences, Inc. Q2 2021 · 10-Q
Revenue$3.29M$3.29M+436.9% vs Q2 2020 Net Income-$6.56M-$6.56MN/M vs Q2 2020 EPS Diluted-$0.25-$0.25N/M vs Q2 2020 Gross Profit$905,053+366.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endovia Health Sciences, Inc. · CIK 1553788 · Engraved from SEC EDGAR
Operating Cash Flowderived-$4,053,083N/M Margins · derivedGross margin27.5%−4.2 pt vs Q2 2020
Operating margin-204.0%−136.2 pt vs Q2 2020
Net margin-199.5%−138.6 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 16, 2021 · 47 d after period end